FIG. 5.

IKK is required for LPS activation of TPL-2. BMDMs (BALB/c) were preincubated with the IKK inhibitor BAY11-7082 or DMSO vehicle control and stimulated with LPS or PMA for the indicted times. BAY11-7082 was used at a concentration of 7.5 μM unless otherwise indicated. (A to C) Total cell lysates were subjected to Western blotting for the indicated proteins. (D) Lysates were immunodepleted of p105 and subjected to Western blotting for TPL-2 and α-tubulin. (E) TPL-2 was immunoprecipitated from total cell lysates and assayed for MEK kinase activity in a coupled MEK/ERK kinase assay as for Fig. 1A.